The Rising Cost of Weight Management and Specialty Drugs: Impact on Private Health Plans
Private drug plans are facing a significant financial shift as the cost of weight management medications and high-cost specialty treatments surges. According to a report from Telus Health, these two categories are expected to have the most substantial impact on private drug plans this year. The landscape is being reshaped by the rapid adoption of GLP-1 receptor agonists and the increasing prevalence of expensive biologic therapies for rare diseases.
The Surge in Weight Management Drug Spending
Spending on weight management drugs has more than quadrupled since 2021. This growth accelerated in 2024 following the May launch of Wegovy (semaglutide), which saw the number of claimants increase by more than 50% within that year. While these medications were traditionally excluded from many private plans—with fewer than half providing automatic coverage—plan sponsors are increasingly reconsidering these exclusions.
Why Coverage is Increasing
Employers and plan sponsors are moving toward coverage for several strategic reasons:
- Comorbidity Reduction: Effective weight loss can lower overall benefit costs by reducing comorbidities associated with obesity, such as arthritis and type 2 diabetes.
- Employee Value: Providing coverage for these medications is becoming a tool for attracting and retaining talent.
- Clinical Efficacy: New medications are demonstrating significant results. For example, adults treated with semaglutide 2.4 mg achieved an average weight loss of 12.4% compared to a placebo, according to clinical trial data.
New and Emerging Therapies
The market continues to expand with more potent options. Zepbound (tirzepatide) received Health Canada approval in May 2025 and entered the Canadian market in July 2025, with clinical trials showing it can lower body weight by 20%. Looking forward, combination therapies are showing average weight loss of 23%, while next-generation drugs targeting multiple hunger-regulating hormones have produced trial results of up to 29% weight loss.
The Burden of High-Cost Specialty Drugs
While weight management drugs affect a large population, specialty drugs drive costs through extreme per-patient pricing. In the U.S., projections for 2025 indicate an 8% surge in healthcare costs, with specialty prescriptions as the primary driver. The number of specialty medications has grown from just 10 in 1990 to over 300 by 2015, with 23 more approved in the first half of 2024 alone.
The Cost of Rare Disease Treatment
Specialty drugs often treat compact patient populations but carry immense price tags. For example:
- General Costs: The average annual cost per specialty drug exceeds $5,000.
- High-End Biologics: Immunosuppressants like Humira (adalimumab) average $77,000 per patient annually. Some one-time curative treatments can exceed $1 million.
- Myasthenia Gravis: In Canada, an estimated 12,000 to 13,000 people live with generalized myasthenia gravis. For the 1,800 patients with refractory disease, annual biologic therapy costs range from $220,000 to $700,000.
New treatments continue to enter the pipeline. Imaavy (nipocalimab) is currently under Health Canada review, with approval expected in early 2026.
Challenges for Employers and Payers
Managing these benefits has become increasingly complex. In the U.S., an estimated 2% to 12% of the population has tried GLP-1s, and 67% of large employers now cover these medications for obesity. However, traditional cost-containment strategies—such as rebates, generics, and specialty drug carve-out programs—are proving insufficient against the current trajectory of pharmacy costs.
Despite the clinical benefits, significant cost and access barriers remain for many patients who meet the criteria for anti-obesity medications (AOMs) to mitigate weight-related morbidity and mortality, as noted in research published via NCBI.
Key Takeaways: Drug Cost Drivers
| Category | Primary Cost Driver | Key Example/Statistic |
|---|---|---|
| Weight Management | High utilization and rapid adoption | Spending quadrupled since 2021 |
| Specialty Drugs | Extreme per-patient pricing | Some treatments exceed $1 million |
| Rare Disease | High-cost biologics | Myasthenia gravis treatments up to $700k/year |
Looking Ahead
The financial pressure on private drug plans will likely persist as more effective, higher-cost medications reach the market. The shift toward covering obesity as a chronic disease reflects a broader medical understanding of its impact on overall health, but it requires plan sponsors to find sustainable ways to balance member needs with unprecedented cost acceleration.